Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease

Abstract We aimed to examine risk of diabetes mellitus (DM) among older adults with Alzheimer's disease receiving 3 types of psychotropic drugs, that is, antipsychotics, antidepressants, and sedative anxiolytics. We retrospectively analyzed data from a hospital-based Clinical Research Center for Dementia of South Korea (CREDOS) study conducted between January 1, 2008 and December 31, 2012. Participants (n = 3042) with Alzheimer's disease were aged 65 or older and had no preexisting history of DM. Development of DM was identified using claims for initiating at least 1 prescription of antidiabetic medications or a diagnosis of DM during the follow-up period. Cox proportional hazards regression was used to demonstrate the Hazard ratio of DM in use of each psychotropic drug. Among the 3042 participants, 426 patients (14.0%) developed DM, representing an incidence rate of 5.2/100 person-years during an average 2.9 years of follow-up period. Among the 3 types of psychotropic drugs, antipsychotic users had a significantly higher risk of DM (hazard ratio = 1.74, 95% confidence interval = 1.10, 2.76) than nonusers, after adjusting covariates. Antidepressants and sedative anxiolytics did not achieve statistical significance. These results suggested that the diabetes risk was elevated in Alzheimer patients on antipsychotic treatment. Therefore, patients with Alzheimer's disease receiving antipsychotic treatment should be carefully monitored for the development of DM.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  B. Kuehn.  FDA warns antipsychotic drugs may be risky for elderly. , 2005, JAMA.

[3]  A. Egberts,et al.  No increased incidence of diabetes in antidepressant users , 2007, International clinical psychopharmacology.

[4]  G. Grossberg,et al.  Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study. , 2009, Journal of the American Medical Directors Association.

[5]  G. Rutten,et al.  Screening for Type 2 Diabetes , 2003 .

[6]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[7]  R. Baldessarini,et al.  Adverse Endocrine and Metabolic Effects of Psychotropic Drugs , 2009, CNS drugs.

[8]  D. Hutchins,et al.  Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. , 2004, Journal of the American Medical Directors Association.

[9]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[10]  Scott D Ramsey,et al.  New‐Onset Treatment‐Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder , 2012, Journal of the American Geriatrics Society.

[11]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[12]  D. Na,et al.  Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study. , 2012, The Journal of clinical psychiatry.

[13]  R. Stewart,et al.  A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. , 2005, Archives of neurology.

[14]  S. Suissa,et al.  Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. , 2009, The American journal of psychiatry.

[15]  F. Verhey,et al.  Prescribing pattern of psychotropic drugs in nursing home residents with dementia , 2011, International Psychogeriatrics.

[16]  A. Thiébaut,et al.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers. , 2012, British journal of clinical pharmacology.

[17]  R. Baker,et al.  Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  M. Woodward,et al.  First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. , 2008, The British journal of psychiatry : the journal of mental science.

[19]  M. Rapoport,et al.  Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review , 2012, International Psychogeriatrics.

[20]  P. Masand,et al.  Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. , 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[21]  B. Kuehn.  New effort to develop molecular tools for early cancer detection under way. , 2005, JAMA.

[22]  M. Freedman,et al.  Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review , 2004, BMJ : British Medical Journal.

[23]  J. Bisbe,et al.  Psychotropic drugs in patients with Alzheimer's Disease: a longitudinal study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain. , 2014, Journal of the American Medical Directors Association.

[24]  Jae-Min Kim,et al.  Comparison of Diagnostic Validities between MMSE-K and K-MMSE for Screening of Dementia , 2003 .

[25]  Kimberley Wilson,et al.  Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. , 2012, Journal of the American Medical Directors Association.

[26]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[27]  Jae Nam Bae,et al.  Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. , 2004, Journal of psychosomatic research.

[28]  Jeff J Guo,et al.  Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. , 2006, The Journal of clinical psychiatry.

[29]  Robert Rosenheck,et al.  Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.

[30]  H. Nasrallah,et al.  Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. , 2002, The Journal of clinical psychiatry.

[31]  Hude Quan,et al.  Cross-National Comparative Performance of Three Versions of the ICD-10 Charlson Index , 2007, Medical care.

[32]  W. S. Clark,et al.  Long‐term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia , 2001, International journal of geriatric psychiatry.

[33]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[34]  Duk L. Na,et al.  A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients , 1997 .

[35]  S. Marder,et al.  Novel antipsychotics and new onset diabetes , 1998, Biological Psychiatry.

[36]  D. Schnur,et al.  Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance , 1989, Psychiatry Research.

[37]  B. Lebowitz,et al.  Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. , 2009, The American journal of psychiatry.

[38]  S. Govoni,et al.  No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease. , 2006, Minerva medica.